Hypera-Sanofi deal faces more scrutiny in Brazil after being declared 'complex'
Hypera's planned buyout of 12 medicine brands from Sanofi Medley Farmacêutica has been declared "complex" by the Brazilian competition authority and will require an in-depth analysis because of what the agency...To view the full article, register now.
Already a subscriber? Click here to view full article